可片的情况:减少儿科的一次性塑料废物
Lydia Lu1, Preeti Jaggi2, Andrew Smelser3
1Pediatric Infectious Disease, Children's Healthcare of Atlanta Inc, Atlanta, USA.
概括
儿科用液体药物对塑料废物有很大的贡献. 使用现有的可配方和调整剂量可以大幅减少这种环境负担.
科学领域:
- 环境科学 环境科学
- 儿科药理学 儿科药理学
- 医疗保健废物管理 医疗保健废物管理
背景情况:
- 儿科药物,通常是液体悬浮剂,是医疗保健塑料废物的主要来源.
- 基于体重的剂量需要液体配方,增加浪费.
- 目前的替代配方和剂量策略未得到充分利用.
研究的目的:
- 评估儿科药物配方对塑料废物的影响.
- 突出替代剂型和剂量策略的不足利用情况.
- 为了证明药物管理中的微小变化如何减少塑料垃圾.
主要方法:
- 关于儿科药物配方和废物产生的文献综述.
- 分析当前的剂量实践和可用替代剂型的可用性.
- 通过优化配方使用,模拟减少塑料垃圾的潜力.
主要成果:
- 液体儿科药物是塑料废物的重要贡献者.
- 片配方和阶梯级剂量建议存在,但不广泛使用.
- 优化配方选择和剂量策略显示了大幅减少塑料垃圾的潜力.
结论:
- 替代儿科药物配方的不足利用有助于塑料垃圾.
- 实施现有的可配方和剂量策略可以减少塑料垃圾.
- 儿科药物管理实践中的小变化可以产生显著的环境效益.
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
411
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
411
Pharmacokinetics in Pediatric Patients: Drug Excretion
340
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
340
Oral Drug Delivery Systems: Introduction
85
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
85
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
387
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
387
Oral Drug Delivery Systems: Continuous-Release Systems
82
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
82
Pharmacokinetics in Pediatric Patients: Drug Metabolism
293
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293


